BACKGROUND: Acute lymphoblastic (ALL) and myeloid leukemia (AML) account for approximately 26% of pediatric cancers. Anthracyclines are widely used to treat these leukemias, but dosing is limited by cardiotoxicity. Data support the efficacy of dexrazoxane as a cardioprotectant in children; however, dexrazoxane use in children is not universally accepted due to concerns about toxicity, impact on the antitumor effect of anthracyclines, and risk of secondary malignant neoplasms (SMN). PROCEDURE: We conducted a retrospective cohort study to describe patterns of dexrazoxane use in pediatric patients with ALL or AML using the Pediatric Health Information Systems (PHIS) database. Patients identified as having de novo ALL and AML at these PHIS hospitals were included. RESULTS: Of 8,733 patients with ALL and 2,556 with AML, 207 (2.4%) and 52 (2.0%) received dexrazoxane, respectively. Dexrazoxane use was greater in older children with ALL and AML and in black patients and males with ALL. Dexrazoxane use varied across time and by region in ALL, but not in AML. Prescribing practices differed across institutions and most patients received the first dose early or late after the start of leukemia treatment. CONCLUSIONS: Dexrazoxane administration is limited in patients with ALL and AML and prescribing practices vary across the country. Further work is necessary to understand how dexrazoxane is used in patients at highest risk of developing cardiotoxicity and to define its true effect on the development of SMNs.
BACKGROUND:Acute lymphoblastic (ALL) and myeloid leukemia (AML) account for approximately 26% of pediatric cancers. Anthracyclines are widely used to treat these leukemias, but dosing is limited by cardiotoxicity. Data support the efficacy of dexrazoxane as a cardioprotectant in children; however, dexrazoxane use in children is not universally accepted due to concerns about toxicity, impact on the antitumor effect of anthracyclines, and risk of secondary malignant neoplasms (SMN). PROCEDURE: We conducted a retrospective cohort study to describe patterns of dexrazoxane use in pediatric patients with ALL or AML using the Pediatric Health Information Systems (PHIS) database. Patients identified as having de novo ALL and AML at these PHIS hospitals were included. RESULTS: Of 8,733 patients with ALL and 2,556 with AML, 207 (2.4%) and 52 (2.0%) received dexrazoxane, respectively. Dexrazoxane use was greater in older children with ALL and AML and in black patients and males with ALL. Dexrazoxane use varied across time and by region in ALL, but not in AML. Prescribing practices differed across institutions and most patients received the first dose early or late after the start of leukemia treatment. CONCLUSIONS:Dexrazoxane administration is limited in patients with ALL and AML and prescribing practices vary across the country. Further work is necessary to understand how dexrazoxane is used in patients at highest risk of developing cardiotoxicity and to define its true effect on the development of SMNs.
Authors: Srigiridhar Kotamraju; Shasi V Kalivendi; Eugene Konorev; Christopher R Chitambar; Joy Joseph; B Kalyanaraman Journal: Methods Enzymol Date: 2004 Impact factor: 1.600
Authors: A Schiavetti; M A Castello; P Versacci; G Varrasso; A Padula; F Ventriglia; B Werner; V Colloridi Journal: Pediatr Hematol Oncol Date: 1997 May-Jun Impact factor: 1.969
Authors: Todd A Ponsky; Zhihuan J Huang; Kory Kittle; Martin R Eichelberger; James C Gilbert; Fredrick Brody; Kurt D Newman Journal: JAMA Date: 2004-10-27 Impact factor: 56.272
Authors: Ching-Hon Pui; John T Sandlund; Deqing Pei; Dario Campana; Gaston K Rivera; Raul C Ribeiro; Jeffrey E Rubnitz; Bassem I Razzouk; Scott C Howard; Melissa M Hudson; Cheng Cheng; Larry E Kun; Susana C Raimondi; Frederick G Behm; James R Downing; Mary V Relling; William E Evans Journal: Blood Date: 2004-07-13 Impact factor: 22.113
Authors: L H Wexler; M P Andrich; D Venzon; S L Berg; L Weaver-McClure; C C Chen; V Dilsizian; N Avila; P Jarosinski; F M Balis; D G Poplack; M E Horowitz Journal: J Clin Oncol Date: 1996-02 Impact factor: 44.544
Authors: O Popelová; M Sterba; P Hasková; T Simůnek; M Hroch; I Guncová; P Nachtigal; M Adamcová; V Gersl; Y Mazurová Journal: Br J Cancer Date: 2009-07-21 Impact factor: 7.640
Authors: Kelly D Getz; Lillian Sung; Todd A Alonzo; Kasey J Leger; Robert B Gerbing; Jessica A Pollard; Todd Cooper; E Anders Kolb; Alan S Gamis; Bonnie Ky; Richard Aplenc Journal: J Clin Oncol Date: 2020-04-28 Impact factor: 44.544
Authors: Steven E Lipshultz; Melissa B Diamond; Vivian I Franco; Sanjeev Aggarwal; Kasey Leger; Maria Verônica Santos; Stephen E Sallan; Eric J Chow Journal: Paediatr Drugs Date: 2014-10 Impact factor: 3.022
Authors: Rebecca Citrin; Kelly D Getz; Yimei Li; Yuan-Shung Huang; Joseph P Horowitz; Alix E Seif; Brian T Fisher; Richard Aplenc Journal: Br J Haematol Date: 2018-04-02 Impact factor: 6.998
Authors: Eric J Chow; Yan Chen; Leontien C Kremer; Norman E Breslow; Melissa M Hudson; Gregory T Armstrong; William L Border; Elizabeth A M Feijen; Daniel M Green; Lillian R Meacham; Kathleen A Meeske; Daniel A Mulrooney; Kirsten K Ness; Kevin C Oeffinger; Charles A Sklar; Marilyn Stovall; Helena J van der Pal; Rita E Weathers; Leslie L Robison; Yutaka Yasui Journal: J Clin Oncol Date: 2014-10-06 Impact factor: 44.544
Authors: Alix E Seif; Dana M Walker; Yimei Li; Yuan-Shung V Huang; Marko Kavcic; Kari Torp; Rochelle Bagatell; Brian T Fisher; Richard Aplenc Journal: Pediatr Blood Cancer Date: 2014-03-26 Impact factor: 3.167